TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01641770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional beverage 10003RF
Description: 2 sachets per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Guidelines for dietary counseling include energy and nutrient requirements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Guidelines for dietary counseling include energy and nutrient requirements.
Study: NCT00274261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonoxynol-9 (N-9)
Description: The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
Study: NCT04071106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric Extract
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study: NCT03579160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% timolol gel with full-thickness skin grafts
Description: Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline dressing
Description: Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
Study: NCT01613729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5 mg
Description: Rosuvastatin 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg
Study: NCT01622153

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Formocresol application after pulpotomy preparation
Description: 1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
Study: NCT04071106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric Extract in Olive oil
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study: NCT01622153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GENTLEray 980 Soft Tissue diode laser
Description: Application to pulp chamber until hemostasis achieved
Study: NCT01596608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MagPro MST)
Description: 100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
Study: NCT00726804

Intervention type: DRUG
Group type: OTHER
Intervention: Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
Description: Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
Study: NCT01457521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen
Study: NCT01190878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% of bromfenac in DuraSite dosed QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% of bromfenac in DuraSite dosed BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DuraSite Vehicle
Description: Vehicle dosed BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom™
Description: 0.09% bromfenac dosed BID
Study: NCT02075450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRcard
Description: CPR Card in place during chest compressions to provide immediate visual feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRcard
Description: CPR Card in place during chest compressions to provide immediate visual feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just in Time Video
Description: CPR Just in Time training video administered before the simulation case

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just in Time Video
Description: CPR Just in Time training video administered before the simulation case
Study: NCT02157298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet. Oral dose
Study: NCT02315378

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ARTAT
Description: A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
Study: NCT04071106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol/ Betamethasone
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study: NCT00091988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle & Behavioral Change Program
Description: Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Education Program
Description: Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
Study: NCT01904097

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 150 mg per oral BID (i.e. twice per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg per oral BID (i.e. twice per day).
Study: NCT04874727

Intervention type: PROCEDURE
Intervention: Mandible slacked and captured with Correct Plus™ Impression Material Superfast
Description: In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
Study: NCT00814398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Embryo Transfer (DET)
Description: Two embryos are transferred during an IVF treatment
Study: NCT01904097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
Study: NCT03515369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Babaodan oral capsule
Description: On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
Study: NCT01856569

Intervention type: OTHER
Intervention: no intervention
Description: in real life of drug,dosage,frequency and duration
Study: NCT00346320

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
Study: NCT03506945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mPEP
Description: Behavioral Activation Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bibliotherapy
Description: Provide educational material on coping strategies pertinent to caregivers
Study: NCT03784469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing body position in bed
Description: The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
Study: NCT00040105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zarnestra (R115777)
Description: Starting Dose:~300 mg by mouth (PO) Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec (Imatinib mesylate)
Description: Starting Dose:~300 mg By Mouth (PO) daily
Study: NCT03429816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
Study: NCT00814398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Embryo Transfer (SET)
Description: A single embryo is transferred during an IVF treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Embryo Transfer (SET)
Description: A single embryo is transferred during an IVF treatment
Study: NCT03855280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APVO101
Description: Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
Study: NCT00783250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol + Tiotropium
Description: Salbutamol 400 micrograms + Tiotropium 18 micrograms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Tiotropium
Description: Placebo via MDI + Tiotropium 18 micrograms
Study: NCT01952431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Lung Capacity (TLC) testing
Description: Comparison of TLC results

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Lung Capacity (TLC) testing
Description: Comparison of TLC results
Study: NCT04156425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram+golimumab
Description: Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Escitalopram+Calcium Tablet
Description: Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram will be administered at 10-20 mg/d during the acute phase.
Study: NCT01122836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Therapeutic Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Therapeutic Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Therapeutic Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Therapeutic Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Therapeutic Massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Therapeutic Massage
Study: NCT03993340

Intervention type: DEVICE
Intervention: Rescue stenting
Description: The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
Study: NCT01949168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol® (ribavirin), 1000/1200mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol® (ribavirin), 1000/1200mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol® (ribavirin), 1000/1200mg by mouth daily
Study: NCT03763123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevacizumab
Description: Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
Study: NCT02707198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kefir
Description: 4 ounces of kefir 3 times a day, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kefir
Description: 4 ounces of kefir 3 times a day, with or without food.
Study: NCT04198441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing
Description: Clean wound, fill wound, dress wound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound dressing
Description: Clean wound, fill wound, dress wound
Study: NCT05146401

Intervention type: OTHER
Intervention: Plasma fatty acid concentration
Description: Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.

Intervention type: OTHER
Intervention: Plasma fatty acid concentration
Description: Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
Study: NCT03059498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral PECS I and II block
Description: A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
Study: NCT02727205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine Transdermal System
Study: NCT04334005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
Study: NCT03483649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study: NCT03059498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral PECS I and II block
Description: A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
Study: NCT03483649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Avastin®
Description: US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Avastin®
Description: EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CN-Avastin®
Description: CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
Study: NCT00845364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo marked PEXSIG
Description: Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
Study: NCT00881296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and carboplatin
Description: Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
Study: NCT04068272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Eyedrop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
Study: NCT01249209

Intervention type: DEVICE
Group type: OTHER
Intervention: lifestyle advice